Drug Discovery Outsourcing Market – By Workflow (Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimisation, Preclinical Development, And Other Associated Workflow), By Therapeutics Area (Respiratory System, Pain & Anaesthesia, Oncology, Ophthalmology, Haematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Dermatology, Anti-Infective, Central Nervous System, Genitourinary System), By Drug Type (Small Mol

Drug Discovery Outsourcing Market is accounted approximate USD 2.5 billion in 2020 and it is expected to reach approximate USD 5.5 billion by 2030 with a CAGR of 8.3% during forecast period.Drug discovery outsourcing is a process of inventing a new medicine in the field of pharmaceuticals, biotechnology, and pharmacology. Drug discovery is a very time consuming, complex, and expensive process and sometimes may have a low success rate. Usually, small pharmaceutical companies develop new drug molecules and sell the patent rights to big companies who can afford to conduct clinical trials and observe whether the drugs are suitable or not. Companies outsource their drug discovery process in order to focus on their core competencies like manufacturing, marketing, and product labelling. The companies providing outsourcing services for drug discovery are established companies with developed infrastructure, developed technological front, and skilled expertise.

Market Segmentation:

On the basis of workflow, the drug discovery outsourcing market is classified into target identification and screening, target validation and functional informatics, lead identification and candidate optimisation, preclinical development, and other associated workflow. Based on therapeutics area, the market can be segmented into respiratory system, pain and anaesthesia, oncology, ophthalmology, haematology, cardiovascular, endocrine, gastrointestinal, immunomodulation, dermatology, anti-infective, central nervous system, genitourinary system, and others. According to drug type, the drug discovery outsourcing market can be bifurcated into small molecules and large molecules. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.

Market Dynamics and Factors:

Rapid progression in technology, reduced approval time, and increasing strategic collaborations in the field of drug development are some of the major factors driving the growth of the drug discovery outsourcing market. For instance, AstraZeneca established multiple outsourcing partnerships with Cancer Research U.K, Cambridge Institute, University of Texas MD Anderson Cancer Centre, Medical Research Council Laboratory of Molecular Biology, and Academic Drug Discovery Consortium in 2014. Cost reduction, access to specialised knowledge and technology, and greater innovation are the major reasons because of which top pharmaceutical companies are opting for outsourcing their drug discovery process. Advancements in emerging technologies such as artificial intelligence and its implementation in drug discovery has also contributed towards the market growth. However, certain restraining factors like high price of drug discovery outsourcing, and increasing risk of drug failure are hindering the growth of the drug discovery outsourcing market. 

Geographic Analysis:

North America is expected to dominate the global drug discovery outsourcing market during the forecast period in terms of market share. The presence of a well-established research infrastructure; existence of a large pool of key players of the pharmaceutical industry; greater adoption of technological advancements; and huge investments in drug discovery research & development are some of the major factors attributing to the market dominance of the region. The Asia Pacific region is anticipated to be the fastest growing market during the forecast period. The growing number of clinical research organisations (CRO), contract manufacturing organisations (CMO), and contract development and manufacturing organisations (CDMO) in the region has resulted in huge trend of outsourcing manufacturing and R&D activities to China and India. This has fuelled the growth of the drug discovery outsourcing market in the APAC region. Government initiatives in the APAC nations to forge ties with U.S pharmaceutical companies is going to propel the market growth in the future. For instance, China launched the Market Authorisation Holder (MAH) pilot program, and as a result investments from venture capitalists increased in the nation’s biotech and pharmaceutical sector.        

Competitive Scenario:

The key players operating in the global drug discovery outsourcing market are –

Charles River Laboratories, Albany Molecular Research, Pharmaceutical Product Development LLC., Jubilant Biosys, Thermo Fisher Scientific Inc., Dalton Pharma Services, Laboratory Corporation of America Holdings, WuXi AppTec, Domainnex, Viva Biotech Ltd.

Drug Discovery Outsourcing Market Report Scope